Apar Kishor Ganti, MD
Dr. Ganti is a physician-scientist, who completed his medical training and a residency in Clinical Pharmacology in Pune, India. He subsequently completed an Internal Medicine residency, a Medical Oncology fellowship and a Master’s Program in Clinical and Translational Research.
He is the Associate Director of Clinical Research at the UNMC Fred and Pamela Buffett Cancer Center. He is a member of the Respiratory Committee of the Alliance for Clinical Trials in Oncology. He is the Chair of the Small Cell Lung Cancer Committee of the National Comprehensive Cancer Network and the VA Clinical Science Research & Development Centralized Data Monitoring Committee.
Dr. Ganti’s research interests are focused on development of novel treatment approaches for patients who are not candidates for standard therapies. His laboratory is focused on identifying novel prognostic and predictive biomarkers for these malignancies.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Jazz PharmaceuticalsTopic:SCLC RWEDate added:12/12/2023Date updated:12/12/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Astra ZenecaTopic:Metastatic NSCLCDate added:12/12/2023Date updated:12/12/2023Relationship end date:12/06/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Cardinal HealthTopic:Meeting highlights lung cancerDate added:12/12/2023Date updated:12/12/2023Relationship end date:10/28/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Flagship BiosciencesTopic:HNSCCDate added:12/12/2023Date updated:12/12/2023Relationship end date:12/31/2021
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Regeneron PharmaceuticalsTopic:NSCLCDate added:12/12/2023Date updated:12/12/2023Relationship end date:12/31/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Mirati TherapeuticsTopic:KRAS G12CDate added:12/12/2023Date updated:12/12/2023Relationship end date:12/31/2021
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Beigene LtdTopic:NSCLCDate added:12/12/2023Date updated:12/12/2023Relationship end date:12/31/2021
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Sanofi GenzymeTopic:NSCLCDate added:12/12/2023Date updated:12/12/2023Relationship end date:12/31/2022
-
Attribution:SelfType of financial relationship:OtherIneligible company:TakedaTopic:IGF1-RDate added:12/12/2023Date updated:12/12/2023Relationship end date:12/31/2022
-
Attribution:SelfType of financial relationship:OtherIneligible company:YmAbs TherapeuticsTopic:DSMC ChairDate added:12/12/2023Date updated:12/12/2023Relationship end date:12/31/2022